# US 7,611,713 B2 · Inducing cellular immune responses to hepatitis B virus using peptide compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,713 B2
- Document ID: US7611713B2
- Status: Granted
- Kind: B2
- Application number: 10/654,601
- Filed: 2003-09-04
- Published: 2005-03-24
- Granted: 2009-11-03
- Earliest claimed: 1999-01-27
- Assignees: Pharmexa Inc.
- Inventors: Alessandro Sette; John Sidney; Scott Southwood; Maria Vitiello; Brian Livingston; Esteban Celis; Ralph Kubo; Howard Grey; Robert Chesnut
- Web page: https://patentgrep.com/patent/US7611713B2

## CPC

- C07K 14/005: from viruses
- A61P 31/12: Antivirals
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2730/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.

## Claims

### Claim 1

An isolated peptide consisting of the oligopeptide LWFHISCLTF (SEQ ID NO:879).

### Claim 2 (depends on 1)

A composition comprising the peptide of claim 1 and a carrier.

### Claim 3 (depends on 1)

A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 1)

A composition comprising the peptide of claim 1 and a liposome.

### Claim 5 (depends on 1)

A composition comprising the peptide of claim 1, wherein the peptide is admixed with at least one other peptide comprising a helper T lymphocyte (HTL) epitope or is joined to at least one other peptide consisting of an HTL epitope.